Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study.

What is known and objectiveSofosbuvir(SOF)-based regimens have been administrated with excellent efficacy in chronic hepatitis C. Few uncontrolled (real-life) studies consider the assessment of renal function when evaluating their post-treatment outcomes. This study aims to evaluate renal biomarkers in a real-life experience with chronic hepatitis C patients treated with SOF therapy in a long-term follow-up. MethodsSerum and urinary biomarkers were analysed before, at the end of therapy (EoT), after 12weeks (sustained virological responseSVR) and one year (1y) post-treatment. Patients were categorized according to baseline glomerular filtration rate (GFRcut-off 45mL/min/1.73m(2)). ResultsNinety-four patients with a mean age of 59.98.5years were included; 98.9% of patients reached SVR. Significant improvement in renal biomarkers was observed in patients with GFR 45mL/min/1.73m(2), as indicated by a progressive increase in mean GFR values until 1y. No evidence of tubular dysfunction was identified. Patients with baseline GFR <45mL/min/1.73m(2) did not experience alterations in renal biomarkers; however, a mean change of +10.7 in GFR values was observed. We noticed significant upper stage transition in the CKD classification, and 58.7% of patients achieved G1 stage at 1y (P<.0001). What is new and conclusionIn a real-life experience of a Brazilian centre, SOF therapy appears to guarantee renal safety for patients with chronic hepatitis C followed until one year after treatment.